| Autor: |
Shutova AS; Endocrinology Research Centre., Dzeranova LK; Endocrinology Research Centre., Vorotnikova SY; Endocrinology Research Centre., Kutin MA; N.N. Burdenko National Medical Research Center of Neurosurgery., Pigarova EA; Endocrinology Research Centre. |
| Jazyk: |
ruština |
| Zdroj: |
Problemy endokrinologii [Probl Endokrinol (Mosk)] 2023 Jun 30; Vol. 69 (3), pp. 44-50. Date of Electronic Publication: 2023 Jun 30. |
| DOI: |
10.14341/probl13222 |
| Abstrakt: |
Prolactinomas are the most common secreting adenomas of the pituitary. In 20% of cases resistance to dopamine-agonists treatment is observed. Medical therapy resistance causes progression of pathological symptoms of hyperprolactinemia and negative topographic and anatomical changes of prolactinoma. The causes of ineffectiveness of dopamine agonists therapy are not fully understood as well as approaches to managing patients require clarification. Current concepts of resistance are based on the data obtained as a result of surgery or after a period of long-term ineffective therapy. Thus, it is very important to find methods of assessing the sensitivity of prolactin-secreting adenomas to drug therapy before surgical treatment. Genetic and immunohistochemical studies find special place among these methods, making it possible to predict adenoma's response to drug therapy at early diagnostic stage. Obtained results will allow us to form personalized algorithm for managing patients. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
